STUDY OBJECTIVE: To assess the feasibility and effectiveness of an emergency department-based, risk-targeted voluntary HIV screening program. METHODS: We prospectively enrolled consenting adult i.v. drug users (IDUs) not known to have HIV infection in the ED of a large inner-city hospital with a high rate of HIV infection among patients during a 10-week trial. Study patients were given confidential HIV pretest and risk-reduction counseling, with 10- to 14-day on-site ED follow-up. Follow-up included posttest counseling, reinforcement of risk-reduction practices, and a +10 incentive to cover transportation costs. HIV seropositive patients were referred to the hospital HIV clinic for further evaluation and treatment. RESULTS: Of 200 eligible IDUs, 168 (84%) consented to HIV testing. Of the 104 (62%) who returned for follow-up, 17 (16%) tested positive for HIV. Of these patients, 6 (35%) kept their initial hospital HIV clinic referral appointment, a rate consistent with the experience of the hospital HIV clinic. Of nine patients in whom CD4+ counts were performed at time of the visit, three (33%) had counts less than 200. At 3-month follow-up, 4 of 20 active IDUs (20%) had reportedly ceased drug use because of the program. The complete program costs was an estimated $16,659, $99 per enrolled patient and $521 per HIV-positive patient. CONCLUSION: An ED-based, risk-targeted HIV screening program is feasible and over time could detect a significant number of asymptomatic HIV-infected individuals, including those who should receive antiretroviral therapy and prophylaxis for Pneumocystis carinii pneumonia therapy (CD4+ count less than 200). An additional benefit of ED-based HIV screening in high-prevalence EDs is the opportunity to conduct successful risk-reduction counseling in some high-risk individuals.
STUDY OBJECTIVE: To assess the feasibility and effectiveness of an emergency department-based, risk-targeted voluntary HIV screening program. METHODS: We prospectively enrolled consenting adult i.v. drug users (IDUs) not known to have HIV infection in the ED of a large inner-city hospital with a high rate of HIV infection among patients during a 10-week trial. Study patients were given confidential HIV pretest and risk-reduction counseling, with 10- to 14-day on-site ED follow-up. Follow-up included posttest counseling, reinforcement of risk-reduction practices, and a +10 incentive to cover transportation costs. HIV seropositivepatients were referred to the hospital HIV clinic for further evaluation and treatment. RESULTS: Of 200 eligible IDUs, 168 (84%) consented to HIV testing. Of the 104 (62%) who returned for follow-up, 17 (16%) tested positive for HIV. Of these patients, 6 (35%) kept their initial hospital HIV clinic referral appointment, a rate consistent with the experience of the hospital HIV clinic. Of nine patients in whom CD4+ counts were performed at time of the visit, three (33%) had counts less than 200. At 3-month follow-up, 4 of 20 active IDUs (20%) had reportedly ceased drug use because of the program. The complete program costs was an estimated $16,659, $99 per enrolled patient and $521 per HIV-positive patient. CONCLUSION: An ED-based, risk-targeted HIV screening program is feasible and over time could detect a significant number of asymptomatic HIV-infected individuals, including those who should receive antiretroviral therapy and prophylaxis for Pneumocystis carinii pneumonia therapy (CD4+ count less than 200). An additional benefit of ED-based HIV screening in high-prevalence EDs is the opportunity to conduct successful risk-reduction counseling in some high-risk individuals.
Authors: Danielle Signer; Stephen Peterson; Yu-Hsiang Hsieh; Somiya Haider; Mustapha Saheed; Paula Neira; Cassie Wicken; Richard E Rothman Journal: Public Health Rep Date: 2016 Jan-Feb Impact factor: 2.792
Authors: Yu-Hsiang Hsieh; Gabor D Kelen; Oliver Laeyendecker; Chadd K Kraus; Thomas C Quinn; Richard E Rothman Journal: Ann Emerg Med Date: 2015-02-23 Impact factor: 5.721
Authors: Michael S Lyons; Christopher J Lindsell; Holly K Ledyard; Peter T Frame; Alexander T Trott Journal: Public Health Rep Date: 2005 May-Jun Impact factor: 2.792
Authors: Roland C Merchant; Bethany M Catanzaro; George R Seage; Kenneth H Mayer; Melissa A Clark; Victor G Degruttola; Bruce M Becker Journal: J Med Screen Date: 2009 Impact factor: 2.136
Authors: Roland C Merchant; George R Seage; Kenneth H Mayer; Melissa A Clark; Victor G DeGruttola; Bruce M Becker Journal: Public Health Rep Date: 2008 Nov-Dec Impact factor: 2.792
Authors: Michael S Lyons; Christopher J Lindsell; Jason S Haukoos; Gregory Almond; Jeremy Brown; Yvette Calderon; Eileen Couture; Roland C Merchant; Douglas A E White; Richard E Rothman; Chris Aldridge; Gregory Almond; Gregory Andrade; Christian Arbelaez; Tom-meka Archinard; Steven I Aronin; Susan Barrera; Moses Bateganya; Joanna Bell-Merriam; Bob Bongiovanni; Kathleen Brady; Bernard Branson; Carol Brosgart; Jeremy Brown; Evan Cadoff; Yvette Calderon; Linda Chaille-Arnold; Ben Cheng; William Chiang; Brittney Copeland; Rosalyn L Cousar; Eileen Couture; Maggie Czarnogorski; Kit Delgado; Emily Erbelding; James Feldman; Osvaldo Garcia; Charlotte A Gaydos; Nancy Glick; Barbara Gripshover; Jason Haukoos; Alisa Hayes; James Heffelfinger; Laura Herrera; Amy Hilley; David Holtgrave; Brooke Hoots; Emily Hopkins; Debra Houry; Debra Howell; Yu-Hsiang Hsieh; Angela B Hutchinson; Blanca Jackson; Michael Jaker; Kerin Jones; Juliana Jung; Linda Kampe; Virginia Kan; Nancy Kass; Gabor D Kelen; Karen Kroc; Ann Kurth; Margaret A Lampe; Jason Leider; Michael Lemanski; Christopher J Lindsell; Michael Lyons; Sandra McGovern; Seth Mercer; Roland Merchant; Nancy Miertschin; Joan Miller; Patricia Mitchell; Sarah Nelson; Linda Onaga; David Paltiel; Sindy Paul; Harold Pollack; Stephen Raffanti; Liisa Randall; Richard Rothman; Akhter Sabreen; Jeffrey Sankoff; Vanessa Sasso; Nathaniel Bernard Saylor; Elissa Schechter; Barbara Schechtman; Steven Schrantz; Alicia Scribner; Judy Shahan; Daniel Skiest; Freya Spielberg; Irijah S Stennett; Patrick Sullivan; Cathalene Teahan; Susan Thompson; Gretchen Torres; Vicken Totten; Krystn Wagner; Rochelle Walensky; Michael Waxman; Andrea Weddle; Douglas White; Tom Widell; James A Wilde; Keith Wrenn; Juliet Yonek Journal: Acad Emerg Med Date: 2008-12-06 Impact factor: 3.451
Authors: Gretchen Williams Torres; Juliet Yonek; Jeremy Pickreign; Heidi Whitmore; Romana Hasnain-Wynia Journal: Public Health Rep Date: 2009 May-Jun Impact factor: 2.792
Authors: Gabor D Kelen; Yu-Hsiang Hsieh; Richard E Rothman; Eshan U Patel; Oliver B Laeyendecker; Mark A Marzinke; William Clarke; Teresa Parsons; Jordyn L Manucci; Thomas C Quinn Journal: AIDS Date: 2016-01-02 Impact factor: 4.177